Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells

Abstract

Immunotherapy has shown great promise in the fight against cancer, as evidenced by the clinical efficacy of chimeric antigen receptor T cells in hematologic malignancies and checkpoint blockade in certain solid tumors. However, a considerable number of patients fail to respond to these therapies. Induction of myeloid-derived suppressor cells (MDSCs) by growing tumors has been shown to be one important factor limiting the efficacy of cancer immunotherapy. Recently, several chemotherapeutic agents used in conventional cancer chemotherapy have been found to reduce MDSC numbers in tumor tissues as well as in the peripheral lymphoid organs, and combining these agents with immunotherapy improved survival of tumor-bearing hosts. In this review, we will highlight the effects of chemotherapeutic agents on MDSC accumulation, and examine the various factors likely to influence these effects.

Keywords: Chemotherapy; immunotherapy; myeloid-derived suppressor cells; overall survival; solid tumors.

Figures

Figure 1.

Chemotherapeutic agents have the potential ability to inhibit MDSCs if administered at the proper time and dose in a proper model with a proper administration mode. At the point when MDSCs are inhibited, immunotherapy addition has an enhanced antitumor efficacy.